液体活检在癌症中的应用:转化科学综述
本综述聚焦循环肿瘤DNA(ctDNA)检测在癌症管理中的转化应用。ctDNA测序可识别非小细胞肺癌、结直肠癌和乳腺癌等癌种的基因变异以指导靶向治疗,其水平变化可提示治疗反应、耐药与复发;但最佳检测时机、影像学阴性时阳性结果的管理及序列监测的成本效益尚不明确。
要点
- ctDNA水平下降提示治疗反应,升高提示耐药或复发。
- 根治性治疗后检出ctDNA与复发和生存较差强相关。
- ctDNA可早于影像学约8.7个月发现结直肠癌分子复发。
核心结论
- ctDNA可帮助临床医生监测癌症进展、检测微小残留病灶并识别可能指导治疗决策的基因变异。
- ctDNA有助于为癌症患者选择最佳治疗及治疗时机,但最佳临床应用仍不明确。
研究设计与样本
- 转化科学综述,汇总ctDNA在癌症监测、残留病灶检测及治疗选择中的证据。
主要发现
- ctDNA测序可识别非小细胞肺癌、结直肠癌和乳腺癌等癌种的基因变异以指导分子靶向治疗选择。
- 在1725例接受治疗的尿路上皮癌患者荟萃分析中,较高ctDNA水平与较差生存结局相关(无病生存风险比20.69 [95%CI, 9.63-44.43];P < .001)。
- 辅助治疗背景下较高ctDNA水平与较差无病生存相关(风险比4.51 [95%CI, 3.04-6.69];P < .001)。
- 转移性疾病系统治疗患者中较高ctDNA水平与较差总生存相关(风险比2.0 [95%CI, 1.25-3.38];P = .004;绝对率未提供)。
- 在130例结直肠癌患者前瞻性队列中,分子复发检测较标准影像监测约早8.7个月(5.5个月 vs 14.2个月;P < .001)。
关键数值与推荐
- 检测到ctDNA早期升高和/或可能 confer 标准治疗耐药的新序列变异,可在影像学发现肿瘤进展前指导治疗决策(如更换新治疗)。
- ctDNA水平不可检测的患者或可停止治疗并接受监测,避免可能产生显著不良反应的不必要化疗暴露。
临床怎么用
- 利用ctDNA基因变异为部分癌种选择分子靶向治疗。
- 通过ctDNA水平动态监测治疗反应、耐药与复发。
- 根治性治疗后检出ctDNA提示高复发风险,可加强监测。
- ctDNA不可检测时可考虑安全停止治疗并监测。
局限性
- ctDNA最佳检测时机尚不明确。
- 影像学无疾病时阳性结果的管理尚不明确。
- 序列监测的成本效益尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Circulating tumor DNA (ctDNA) evaluation, in which fragments of tumor DNA circulating in a patient's bloodstream are extracted and analyzed, can be used to monitor cancer progression, detect residual cancer after treatment, and identify genetic changes within cancer cells that could affect treatment response. OBSERVATIONS: ctDNA sequencing identifies cancer cell gene variants that inform the selection of molecularly directed therapies in several types of cancer, including non-small cell lung cancer, colorectal cancer, and breast cancer. Increases or decreases in ctDNA levels can indicate treatment response (ctDNA decrease) or cancer cell resistance and recurrence (ctDNA increase). Detecting ctDNA after curative intent therapy correlates strongly with cancer recurrence and poorer survival. In a meta-analysis of 1725 patients undergoing treatment for urothelial carcinoma, higher ctDNA levels were associated with poorer survival outcomes (hazard ratio for disease-free survival, 20.69 [95% CI, 9.63-44.43]; P < .001). This association was also observed in adjuvant settings (hazard ratio for disease-free survival, 4.51 [95% CI, 3.04-6.69]; P < .001) and in patients undergoing systemic therapy for metastatic disease (hazard ratio for overall survival, 2.0 [95% CI, 1.25-3.38]; P = .004; absolute rates not available). ctDNA detection may indicate minimal residual disease, defined as cancer cells detectable only by highly sensitive testing (eg, detection of 1 cancer cell in a population of 1 million normal cells) before disease progression is identified with imaging. Detecting an early increase in ctDNA and/or a novel sequence variation that may confer resistance to standard treatment can guide therapeutic decisions, such as changing to a new treatment, before tumor progression is detectable with conventional imaging. In a prospective cohort study of 130 patients with colorectal cancer, molecular relapse of disease was detected approximately 8.7 months earlier compared with standard-of-care imaging surveillance (5.5 months vs 14.2 months; P < .001). Similarly, patients with undetectable ctDNA levels may be able to discontinue therapy and be monitored, preventing potentially unnecessary exposure to chemotherapy that may have substantial adverse effects. However, the optimal timing of ctDNA testing, management of positive results in the absence of radiographic disease, and the cost-effectiveness of serial monitoring remain unclear. CONCLUSIONS AND RELEVANCE: ctDNA, consisting of small DNA fragments from cancer cells that can be analyzed in human blood, can help clinicians monitor cancer progression, detect minimal residual cancer, and identify genetic variants that may help guide treatment decisions. Use of ctDNA may help select best treatment and timing of therapy for a patient with cancer, but optimal clinical applications remain unclear.
引用
- Mezzanotte-Sharpe J, Piemonte K, Park BH, et al. Liquid Biopsies for Cancer: A Translational Science Review. JAMA. 2026. PMID: 42574031. doi:10.1001/jama.2026.13898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。